Ideaya Biosciences Inc (IDYA)
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
Designated Market Maker (DMM) Obligations: United States Public Holiday on 19 June 2026
Johnson & Johnson - Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
Comtech Announces Financial Results for Third Quarter of Fiscal 2026
Target Teams Up with Isaac Mizrahi to Shape the Future of Accessible Design
Halozyme - Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Gilat to Acquire Comtech’s Satellite & Space Communications Segment Creating a Leading Provider of Advanced Defense and Satellite Communications Solutions
Brand Engagement Network (NASDAQ: BNAI) Selected for Membership in Russell 3000® and Russell 2000® Indexes
Powerfleet Reports Results for Fourth Quarter and Full-Year Fiscal 2026
Comtech Announces Definitive Agreement to Sell Most of Its Satellite and Space Communications Business to Gilat